AMSTERDAM, the Netherlands--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by Leandro Cerchietti, MD, Richard A.

荷兰阿姆斯特丹--（商业新闻短讯）--Scient Biotech是发现基因修饰剂开发治疗严重疾病的先驱，今天宣布了其主要小分子QPCTL抑制剂SC-2882的阳性临床前数据。今天，医学博士Leandro Cerchietti，Richard A。

Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. The new preclinical data covers results for SC-2882, Scenic’s first-in-class QPCTL inhibitor, as a potential new treatment approach for diffuse large B-cell lymphoma (DLBCL).

在圣地亚哥举行的第65届美国血液学会（ASH）年会和博览会上，纽约威尔·康奈尔医学院（WeillCornell Medicine）血液学和肿瘤学副教授斯特拉顿（Stratton）。新的临床前数据涵盖了Scient的第一类QPCTL抑制剂SC-2882的结果，作为弥漫性大B细胞淋巴瘤（DLBCL）的潜在新治疗方法。

DLBCL accounts for 25-30% of all non-Hodgkin lymphoma cases, making it the most common cancer of the lymphatic system characterized by rapidly growing tumor mass or enlarging lymph nodes in a nodal or extranodal site..

DLBCL占所有非霍奇金淋巴瘤病例的25-30%，是淋巴系统中最常见的癌症，其特征是肿瘤肿块迅速增长或淋巴结或结外部位淋巴结肿大。。

“Treatment with SC-2882 in a DLBCL mice model achieved a significant decrease in tumor growth and an increase of CD3+ T cell infiltration within the tumor microenvironment, along with a reduction in immunosuppressive immune cells. This suggests that QPCTL inhibition in DLBCL has anti-lymphoma effects and holds potential as a new therapeutic avenue for this type of cancer,” commented Leandro Cerchietti, MD, Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York, and presenter at the 65th ASH Annual Meeting & Exposition..

Leandro评论道：“在DLBCL小鼠模型中用SC-2882治疗可显着降低肿瘤生长，增加肿瘤微环境中CD3+T细胞的浸润，同时减少免疫抑制性免疫细胞。这表明DLBCL中的QPCTL抑制具有抗淋巴瘤作用，并有望成为这种癌症的新治疗途径。”医学博士Cerchietti，纽约威尔·康奈尔医学院血液学和肿瘤学副教授，第65届ASH年会和博览会主持人。。

“The positive preclinical data presented today constitute a major step forward in the advance of SC-2882 as a potential treatment for DLBCL, an indication with high unmet medical need especially in post-CART relapsed or refractory DLBCL patients, as well as in earlier lines of treatment with non-chemotherapy or immuno-oncology-based approaches.

“今天提供的积极的临床前数据是SC-2882作为DLBCL潜在治疗方法的一个重大进步，这是一个未满足医疗需求的指标，特别是在CART后复发或难治性DLBCL患者中，以及早期使用非化疗或基于免疫肿瘤学的方法进行治疗。

QPCTL was identified as a new immuno-oncology target through our proprietary Cell-Seq platform, and we view these results as a validation for our approach and our earlier-staged Cell-Seq-generated programs in rare diseases,” commented Jens Würthner, MD, PhD, CMO of Scenic Biotech. “As we finalize IND-enabling studies for SC-2882, we look forward to submitting our initial clinical trial filing to the regulatory authorities in 2024 and moving into clinical evaluation.”.

通过我们专有的Cell-Seq平台，QPCTL被确定为一种新的免疫肿瘤学靶标，我们将这些结果视为对我们的方法和我们在罕见疾病中早期阶段Cell-Seq生成程序的验证，”Scientive Biotech的CMO医学博士Jens Würthner评论道。“随着我们完成SC-2882的IND启用研究，我们期待着在2024年向监管机构提交我们的初始临床试验申请，并进入临床评估。”。

QPCTL is an intracellular enzyme that modulates the activity of CD47 and several chemokines in cancer leading to immune escape of cancer cells. SC-2882 targets QPCTL and thereby inhibits the CD47-SIRPα “don’t eat me” checkpoint and lowers immune suppression in the tumor microenvironment. Analysis of DLBCL patient datasets revealed that QPCTL expression negatively correlates with overall and progression-free survival.

QPCTL是一种细胞内酶，可调节癌症中CD47和几种趋化因子的活性，从而导致癌细胞的免疫逃逸。SC-2882靶向QPCTL，从而抑制CD47-SIRPα“不吃我”检查点，并降低肿瘤微环境中的免疫抑制。对DLBCL患者数据集的分析显示，QPCTL表达与总体和无进展生存率呈负相关。

In a murine model of DLBCL, SC-2882 treatment led to a significant decrease in tumor growth with no evidence of systemic toxicity. Moreover, evaluation of the tumor microenvironment (TME) showed an increased CD3+ T cell infiltration and a reduction in tumor-associated macrophages and regulatory T cells in SC-2882-treated mice, compared to control.

在DLBCL的小鼠模型中，SC-2882治疗导致肿瘤生长显着降低，没有全身毒性的证据。此外，与对照相比，肿瘤微环境（TME）的评估显示SC-2882处理的小鼠中CD3+T细胞浸润增加，肿瘤相关巨噬细胞和调节性T细胞减少。

These results imply SC-2882 exhibits an anti-tumor effect that involves modulation of immunosuppression in the TME..

这些结果意味着SC-2882具有抗肿瘤作用，涉及TME中免疫抑制的调节。。

The data was described today in an oral presentation by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York, at 9:30 AM PST/ 18:30 CET during session 605 entitled “Molecular Pharmacology and Drug Resistance - Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma”..

这些数据今天由纽约威尔康奈尔医学院血液学和肿瘤学副教授Richard A.Stratton医学博士Leandro Cerchietti在题为“分子药理学和耐药性-淋巴肿瘤：淋巴瘤和多发性骨髓瘤的新型治疗方法”的第605次会议期间于太平洋标准时间上午9:30/欧洲中部时间18:30进行了口头介绍。。

About Scenic Biotech

关于风景生物技术

Scenic Biotech is at the forefront of identifying genetic modifiers, naturally occurring genes that compensate for mutations responsible for severe diseases. Leveraging our proprietary Cell-Seq platform, we develop small molecule inhibitors that mimic the modifier effect and neutralize the genetic disease phenotype.

Scientive Biotech在鉴定遗传修饰因子方面处于领先地位，遗传修饰因子是天然存在的基因，可以补偿导致严重疾病的突变。利用我们专有的Cell-Seq平台，我们开发了模拟修饰作用并中和遗传疾病表型的小分子抑制剂。

As we advance a robust pipeline of first-in-class modifier therapies, we aim to re-balance health in patients with life-threatening inherited disorders..

随着我们推进一流改良疗法的强大渠道，我们的目标是重新平衡威胁生命的遗传性疾病患者的健康。。